Navigation Links
Amarin Provides Business Update and Announces Implementation of Reverse Stock Split
Date:1/18/2008

LONDON, January 18 /PRNewswire-FirstCall/ -- Amarin Corporation plc (NASDAQ: AMRND) today announced that, at a General Meeting held yesterday, its shareholders approved a 1 for 10 reverse split of each of its Ordinary Shares. The reverse split became effective as of the close of business yesterday, January 17, 2008.

Thomas Lynch, Amarin Chairman and Chief Executive Officer, commented "We are very pleased to report that over 95% of the votes cast by our shareholders approved the one-for-ten reverse stock split. We have made good progress in recent months expanding our management team and broadening our pipeline and look forward to executing on our strategy which we believe will drive shareholder value in 2008."

Under customary Nasdaq practice, with effect from today, January 18, 2008, and for a period of 20 trading days, a "D" will be appended to Amarin's Nasdaq ticker symbol and during that period Amarin's Nasdaq ticker symbol will appear as "AMRND".

Pipeline Update

Through 2007, the Company embarked upon a program of broadening its development pipeline with the objective of having multiple late stage programs with an appropriate balance of portfolio risk.

This was facilitated by the achievement of a number of important milestones. Firstly, the completion of a comprehensive analysis of the 12-month data from the US Phase III trial of Miraxion (AMR101) in Huntington's disease (HD) showing a statistically significant benefit with Miraxion over longer periods of treatment, and the corresponding feedback from the U.S. Food and Drug Administration (FDA).

Amarin also conducted a thorough analysis and re-configuration of its existing pipeline from which the Company's cardiovascular initiative was launch
'/>"/>

SOURCE Amarin Corporation Plc
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Amarin to Commence Phase II Trial With AMR101 in Age Associated Memory Impairment
2. Amarin Signs Agreement to Acquire Ester Neurosciences
3. Amarin Corporation to Present at Acumen BioFin Rodman & Renshaw Ninth Annual Healthcare Conference
4. Amarin Announces Initiation of Cardiovascular Development Strategy
5. Amarin to Present at 4th Annual Bio Investor Forum
6. Amarin Announces Publication of Pre-Clinical Memory Data in Journal of Neurochemistry
7. YM BioSciences provides update on AeroLEF(TM) clinical development program
8. ViroPharma Provides 2008 Outlook
9. Evotec Provides Update on Planned NASDAQ Listing in the Context of its Announced Acquisition of Renovis
10. Cinpathogen Provides Clinical Diagnostic Consulting Services to Shanghai Area Hospitals
11. Strativa Pharmaceuticals, the Proprietary Products Division of Par Pharmaceutical, Provides an Update on Development Status of Pafuramidine and Other in-Licensed Products
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/17/2014)... , Sept. 17, 2014  PDL BioPharma, Inc. (PDL) (NASDAQ: ... registered accounting firm, Ernst & Young LLP ("EY") that it ... in a letter delivered to the Company on September 15, ... 16, 2014.  PDL has issued the following ... received a number of inquiries on the reason for the ...
(Date:9/17/2014)... 17, 2014 A long-term retrospective study ... irradiation (APBI) via interstitial brachytherapy suggests that women ... nodes could be suitable to receive the treatment. ... place these patients in the "unsuitable" category for ... ASTRO meeting, Beaumont Health System,s Peter Y. ...
(Date:9/17/2014)... 17, 2014 The global consumption of squalene / ... is a natural skin-identical chemical that finds applications in various ... supplements, pharmaceuticals, and in other applications like high grade lubrication, ... a few major players and is regionally segregated. Sophim ( ... Oil Co. Ltd. ( Japan ), SeaDragon Marine ...
(Date:9/17/2014)... , Sept. 17, 2014 /PRNewswire/ - Oncothyreon Inc. ... intends to offer and sell shares of its Common ... but concurrent underwritten public offerings.  The Series A Convertible ... Oncothyreon Common Stock, provided that conversion will be prohibited ... would beneficially own more than 4.99% of the Common ...
Breaking Biology Technology:PDL BioPharma Issues Statement on Resignation of Ernst and Young as Corporate Auditors 2PDL BioPharma Issues Statement on Resignation of Ernst and Young as Corporate Auditors 3Partial Breast Irradiation With Interstitial Brachytherapy Appears Appropriate For Women Previously Considered Unsuitable 2Partial Breast Irradiation With Interstitial Brachytherapy Appears Appropriate For Women Previously Considered Unsuitable 3Partial Breast Irradiation With Interstitial Brachytherapy Appears Appropriate For Women Previously Considered Unsuitable 4Squalene Market by Source (Animal & Vegetable) & by End-user Industry (Cosmetics, Pharmaceuticals & Food Industry) - Global Trends & Forecasts to 2019 2Squalene Market by Source (Animal & Vegetable) & by End-user Industry (Cosmetics, Pharmaceuticals & Food Industry) - Global Trends & Forecasts to 2019 3Oncothyreon Announces Proposed Public Offerings 2
... made the honor roll of a national economic development assessment ... , ,The 2006 Development Report Card for the States, released ... the state an A in performance and Bs in business ... there were a few stinkers hidden in the subcategories that ...
... Lori Holder-Webb , an assistant professor of accounting and ... Business, is part of a four-person research team recently ... NASD Investor Education Foundation recently awarded more ... both of the School of Management of Boston College, ...
... Visonex will receive $109,000 in loans ... office said. The company provides web-based disease management software for ... to hire nine people as part of its current growth ... money includes: , , $100,000 loan from the Technology ...
Cached Biology Technology:
(Date:9/17/2014)... health care to reproductive technologies, the justice and ... of people to identify key issues, articulate their ... find the most defensible ways forward. But what ... societal conversations?, The Hastings Center and the Presidential ... teamed up to publish a series of essays ...
(Date:9/17/2014)... of the Santa Ana Wildfire Threat Index a ... the powerful, hot, dry Santa Ana wind, which can ... introduced Sept. 17 by the U.S. Forest Service, in ... , The index includes four classification levels ranging from ... fire agencies and other emergency responders, the media and ...
(Date:9/17/2014)... the Arts and Humanities has received a $260,000 grant ... project, "The Boundaries of the Human in the Age ... a wide-ranging series of events aimed at exploring two ... artists and researchers who are exploring the boundaries of ... humanism, and the other involves the increasingly influential hypothesis ...
Breaking Biology News(10 mins):Why bioethics literacy matters 2Why bioethics literacy matters 3UCLA scientists play key role in developing new Santa Ana Wildfire Threat Index 2Mellon Foundation awards grant for major project in the humanities and sciences 2
... of life imitating art, avian scents given off by male ... Michigan State University researcher revealed the process of how males ... issue of Behavioral Ecology . Scents are used in ... evaluating mates. But this is the first study of its ...
... dopamine is best known for its roles in the ... reward, learning and memory. Now, Vanderbilt University Medical Center ... in the kidneys is important for renal ... published in the July Journal of Clinical Investigation ...
... July 19, 2011 -- How is it that a disc-like ... into an elongated embryo? This mechanism is a mystery ... The first significant step towards understanding the issue was made ... embryologists Hans Spemann and Hilde Mangold. The two used early ...
Cached Biology News:Avian 'Axe effect' attracts attention of females and males 2Kidney dopamine regulates blood pressure, life span 2Hebrew U. scientists show for first time how early human embryo acquires its shape 2
Mouse monoclonal antibody raised against a partial recombinant PRG4. NCBI Entrez Gene ID = PRG4...
Mouse monoclonal antibody raised against a partial recombinant SCARB2. NCBI Entrez Gene ID = SCARB2...
...
Mouse polyclonal antibody raised against a partial recombinant CSRP3. NCBI Entrez Gene ID = 8048...
Biology Products: